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Mexico and Mitochondrial Replacement Techniques: What a Mess 
 
Abstract 
Background 
The first live birth following the use of a new reproductive technique, Maternal Spindle 
Transfer (MST), which is a Mitochondrial Replacement Technique (MRT), was accomplished 
by dividing the execution of the MST procedure between two countries, the US and Mexico. 
This was done in order to avoid US legal restrictions on this technique.      
Sources of data 
Academic articles, news articles, documents obtained through freedom of information 
requests, laws, regulations, and national reports. 
Areas of agreement 
MRTs are new reproductive techniques that present novel ethical and legal challenges, since 
genetic material from three people is employed to create a child.   
Areas of controversy 
Could the first MST procedure that culminated in a live birth negatively impact reproductive 
medicine in Mexico? 
Growing points 
The US and Mexico need specific and clear legislation on MRTs, in order for such techniques 
not to be governed by prior existing legislation on assisted reproduction that is inadequate 
for dealing with the new challenges that these techniques present.  
Areas timely for developing research  
There is a pressing need for work to be done on the international governance of new 
reproductive techniques.  
 
Keywords:  Mitochondrial Replacement Techniques, Mitochondrial Replacement Therapy, 
Mitochondrial Donation, Mitochondrial DNA diseases, Mitochondria, three person IVF, 
Nuclear Genome Transfer 
 
Introduction 
On the 6th of April 2016 a boy was born in the US after a Mitochondrial Replacement 
Technique (MRT).[1] When the birth was reported, five months afterwards, the news left the 
scientific world astonished for two reasons.[2] First, this case was proof of concept that a live 
birth in humans could follow after an MRT, in this specific case Maternal Spindle Transfer 
(MST). Second, the scientists behind this case divided the execution of the whole procedure 
between two separate countries, the US and Mexico, in order to avoid US legal restrictions 
on MRTs. This review concentrates on the second point, and more specifically, on the 
This is an unedited version of the accepted manuscript, scheduled for publication in the British Medical 
Journal.  
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regulation of MRTs in Mexico and on how the first live birth following an MRT could adversely 
affect reproductive medicine in that country.   
The review is divided in four sections. First, I put forward a basic description of mitochondria 
and mitochondrial diseases. Second, I present, in a schematic way, four MRTs that could allow 
women whose oocytes contain deleterious mutations of the mitochondrial DNA (mtDNA) to 
have healthy genetically related children. Third, I analyse how the first live birth following an 
MRT was presented in the media, and how this news could impact reproductive medicine in 
Mexico. Finally, I discuss why the way in which this MRT procedure was carried out should 
not be a blueprint for any further advances within reproductive medicine.  
Mitochondria and Mitochondrial Diseases 
Mitochondria are cellular organelles inherited via the maternal line. Their most important 
function known to date is to produce the energy, in the form of adenosine triphosphate, that 
the human body (i.e. cells, tissues and organs) needs to operate. Contrary to other organelles, 
mitochondria possess their own DNA: mtDNA. Thus, in all human cells (except erythrocytes, 
which do not possess DNA) there is nuclear DNA (nDNA) and mtDNA. Whereas nDNA 
constitutes, roughly, 99.9% of a cell’s DNA, mtDNA comprises the other .1%.[3] There are 
many mitochondria in each nucleated cell; in the oocyte, more specifically, there are around 
200,000 to 300,000 mitochondria.[4] And furthermore, there is not just one human mtDNA 
haplogroup; to this date 30 different mtDNA haplogroups have been discovered.[5] Finally, 
mitochondrial function does not solely depend on the expression of mtDNA, but rather it 
depends on the expression of genes both in the nDNA and the mtDNA. “There are more than 
1500 mitochondrial proteins, most of which are nuclear-encoded, with only 13 encoded by 
mitochondrial DNA (mtDNA).”[6] 
Mitochondrial diseases are a diverse group of diseases. They impact energy metabolism, and 
can be caused by mutations in the nDNA or the mtDNA. In this paper I will only focus on 
mitochondrial diseases caused by deleterious mutations of the mtDNA: mtDNA diseases. The 
severity of mtDNA diseases can range from mild to fatal, and their onset can occur during 
childhood or later in life. In fact, mtDNA mutations can cause miscarriage and stillbirth. To 
which degree human organs are affected by deleterious mutations of the mtDNA depends on 
their energetic needs. Organs with high energy requirements are those that are the most 
sensitive to such mutations of the mtDNA (e.g. the brain).  
Because mitochondria are transmitted via the maternal line “disease-causing alleles carried 
by a woman can be passed on to all her offspring with no ability for the father’s (likely) wild-
type alleles to compensate”.[7] Dementia, deafness, stroke, blindness, Leber’s hereditary 
optic neuropathy, and Leigh’s syndrome (among other conditions and syndromes) all can 
occur because of deleterious mutations of the mtDNA. There are many mitochondria in each 
nucleated cell and mutations in the mtDNA can happen across all mitochondrial genomes, 
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known as homoplasmy, or they can occur in some mitochondrial genomes, known as 
heteroplasmy. In cases of heteroplasmy, the number of mitochondria with deleteriously 
mutated DNA can vary across cells and tissues. This happens because during the cell division 
process mitochondrial segregation occurs by means of the bottleneck effect.[8] Finally, it 
must be noted that at the present time there is no cure for mtDNA diseases; existing 
treatments aim at easing the gravity of the recurring symptoms. 
Women who know that their oocytes have a significant amount of deleteriously mutated 
mitochondria have different reproductive options.[9] They can choose not to reproduce. They 
can choose to have a child by means of sexual intercourse, and risk having a child with a 
mtDNA disease. These women have other reproductive, and family making, options if they 
want to have a child without a mtDNA disease, depending on: what kind of parental link they 
want to share with their children, if they have access to specialized medicine, and the laws 
concerning assisted reproduction to which they are subject. These women can: adopt, adopt 
an embryo, or resort to a donated egg. These three options entail that they would not be 
genetically related to their children. In addition to the former, they can also seek to have a 
child with whom they share a genetic link but without a mtDNA disease. Those couples who 
already have a child with a mtDNA disease can resort to oocyte sampling, in order to assess 
the possible risk of recurrence. They can also, depending on the type of mtDNA mutation and 
its prevalence across the mitochondria, undergo chorionic villus sampling or amniocentesis, 
and afterwards choose for or against termination. Or they can opt for preimplantation genetic 
diagnosis (PGD) and then select to transfer only those embryos with a non-existent or very 
minor mtDNA mutated load (this option is not available for women with homoplasmic 
deleterious mutations). It must be noted that the prediction of a future mtDNA disease by 
means of PGD depends on the availability of data on the mtDNA mutation in question.[10] In 
conclusion, the use of the former techniques would guarantee that there is a genetic link 
between mother and child, but because of the nature of mtDNA diseases they cannot always 
be employed when the main aim is to have a child without a mtDNA disease. 
Mitochondrial Replacement Techniques  
 
Four techniques have recently been developed which can aid women whose oocytes contain 
deleterious mtDNA mutations to have genetically related children without a mtDNA disease. 
The successful use of these techniques (i.e. the creation of a child without a mtDNA disease) 
does not require specific knowledge about the type of mtDNA mutation, nor its prevalence 
across all mitochondria. These techniques have been collectively called Mitochondrial 
Replacement Techniques (MRTs), although this terminology has been contested.[11, 12] They 
are: maternal spindle transfer (MST), pronuclear transfer (PNT), first polar body transfer 
(PB1T) and second polar body transfer (PB2T). All these techniques work by rehousing the 
nuclear material of the intending mother (or intending couple) into an enucleated cell with 
healthy mitochondria. The following description of MRTs is schematic in nature; for a detailed 
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account see Greenfield et al.’s Assisted reproductive technologies to prevent human 
mitochondrial disease transmission.[13] 
 
In MST, assisted reproductive techniques (ARTs) are used to obtain eggs from a healthy donor 
and the intending mother (i.e. the woman whose oocytes contain deleteriously mutated 
mtDNA). The nuclear material of both eggs (at the metaphase II stage) is extracted. The 
intending mother’s enucleated cell is discarded, along with the donor’s nuclear material. 
Afterwards, the intending mother’s nuclear material is transferred to the donor’s enucleated 
oocyte. The new oocyte, which possesses healthy mitochondria and the nuclear material from 
the intending mother, can now be fertilized in vitro and then transferred.[14] 
 
In PNT, ARTs are employed to create two zygotes: one with the intending mother’s egg and 
another one with a donated egg. The sperm can be provided by the intending father or a 
donor. After fertilization, but prior to the breakdown of the pronuclear membranes, the 
maternal and paternal pronuclei of both zygotes are extracted. The pronuclei of the zygote 
produced with the donor’s egg are discarded, just as the enucleated zygote produced with 
the intending mother’s egg. Afterwards, the pronculei that were contained in the zygote 
produced with the intending mother’s egg are transferred into the enucleated zygote 
produced with the donated egg. Finally, the new zygote is transferred to the intending mother 
or a surrogate.[15] 
 
Polar body transfer techniques are the newest MRTs. The developing oocyte, contrary to most 
human cells which contain two sets of 23 chromosomes, has already duplicated its 
chromosomes so it possesses four sets of 23 chromosomes. During the oocyte development 
process these four sets will separate, and half of them will end in a small daughter cell: the 
first polar body. When  normal fertilization process takes place this first polar body will not 
be part of any resulting embryo. Now, the second polar body is produced during the 
fertilization process. The two remaining sets of maternally inherited chromosomes again 
divide in half. One set will become the maternal nuclear DNA, remaining within the just 
created zygote, whereas the other set will be stored within a small daughter cell: the second 
polar body.[16]  
 
PB1T is similar to MST. In PB1T, ARTs are used to obtain eggs from a healthy donor and the 
intending mother. The nuclear material from the donated egg is extracted, and the first polar 
body from the intending mother’s egg is extracted too. The intending mother’s egg is 
discarded, just as the donor’s nuclear material. Then, the first polar body is transferred to the 
donor’s enucleated oocyte. The new oocyte, which possesses healthy mitochondria and the 
nuclear material from the intending mother (which came from the first polar body) can now 
be fertilized in vitro and then transferred.[16] 
 
5 
 
PB2T is similar to PNT. In PB2T, ARTs are employed to create two zygotes, one with the 
intending mother’s egg and another one with a donated egg. After fertilization, the second 
polar body is removed from the zygote created with the intending mother’s egg. The maternal 
pronucleus and the second polar body of the zygote produced with the donor’s egg are also 
removed, thus only the paternal pronucleus remains within the cell. The maternal pronucleus 
and the second polar body of the cell produced with the donor’s egg, and the zygote produced 
with the intending mother’s egg (now without the second polar body) are discarded. 
Afterwards, the second polar body is transferred into the zygote produced with the donor’s 
egg, which at this point only contains the paternal nuclear material. The new zygote is 
transferred to the intending mother or a surrogate.[16] It is worth mentioning that PB1T can 
be performed in conjunction with MST, and that PB2T can be performed in conjunction with 
PNT. This is possible since an oocyte will contain a maternal spindle and a PB1, and a zygote 
will contain a maternal pronucleus and a PB2, see [Fig. 1].   
 
 
Figure 1: Protocols for mitochondrial replacement therapy. (a) Schematic of PNT. (b) Schematic of MST. 
(c) PB1T and MST. A combination of both techniques can be used to create two reconstituted donated 
oocytes from one oocyte carrying mutated mitochondria. (d) PB2T and PNT. As in c, the genetic material 
from one patient oocyte could be used in two donated oocytes to create two reconstituted embryos 
with normal mitochondria. (Reprinted by permission from Springer Nature Terms and Conditions for 
RightsLink Permissions Springer Customer Service Centre GmbH: Springer Nature, NATURE 
BIOTECHNOLOGY, Assisted reproductive technologies to prevent human mitochondrial disease 
transmission, 2017.) 
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One of the reasons why scientists have looked into the latter two techniques (PB1T and PB2T) 
is because the polar bodies contain very little cytoplasm and thus the possibility of mutated 
mitochondrial carryover appears to diminish greatly.[17] This is important since if there were 
to be a large carryover of mutated mitochondria during any of the MRT processes a mtDNA 
diseases could manifest.[18] In a recent experiment, mitochondrial reversion was observed 
in human embryonic stem cell lines; in it the carried over deleteriously mutated mitochondria 
expanded preferentially during cell division.[19]  
  
Finally, it must be clear that any offspring product of an MRT would possess DNA from three 
different persons – nDNA from two persons and mtDNA from a third person – and that the 
third party mitochondria will be passed down to future generations via the maternal line. The 
former has sparked a lively philosophical debate on whether such children indeed have three 
biological/genetic parents or not.[20–22] 
 
A Baby is Born 
 
On the 27th of September 2016 Jessica Hamzelou, writing for New Scientist, broke the news 
about the first live birth following an MRT, in this case MST. Let us remember that the baby 
was born on the 6th of April 2016. In her article Hamzelou did not mention where the baby 
was born, but stated that he was born to a Jordanian couple and that the treatment had 
happened in Mexico: “the birth of the child, whose Jordanian parents were treated by a US-
based team in Mexico” and “[n]either method [MST and PNT] has been approved in the US, 
so Zhang went to Mexico instead”.[2] Up to that point the Jordanian couple had lost two 
children to Leigh syndrome, and the woman had had multiple miscarriages.  
 
The news impacted the scientific community because it was the first proof of concept that 
MRTs could end in a live human birth.[23] They were also shocking in that the scientific 
community presumed that the first MRT birth, if there was going to be any, would occur in 
the UK. This was a common assumption since work on MRTs, and their potential, had been 
explored in the UK since the 2000s.[24] And because by February 2015 the House of Lords 
and the House of Commons had voted in favour of passing the Human Fertilisation and 
Embryology (Mitochondrial Donation) Regulations 2015, which came into force the 29th 
October 2015.[25]  
 
In order to lawfully perform an MRT in the UK: a) a clinic requires that its licence be amended 
in order for MRTs to be carried out there, by the Human Fertilisation and Embryology 
Authority’s (HFEA) license committee, and b) the individual in question requires approval by 
the HFEA’s statutory approvals committee.[26] Once these two hurdles have been surpassed 
an MRT procedure can take place. Newcastle Fertility Centre was the first centre whose 
licence was amended in order for it to carry out MRTs; and in February 2018 two women were 
granted approval to undergo an MRT procedure there.[27] It must be noted that in the UK 
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only MST and PNT can be legally employed, and that they can only be used to prevent the 
transmission of serious mtDNA diseases, their use for treating infertility is not allowed. 
 
Returning to our case, the lead scientist behind the US/Mexico international MRT case was 
US based Dr. John Zhang. Dr Zhang is a fertility expert, who is also the Founder/CEO of the 
private fertility clinic New Hope Fertility Center, in New York City. Before aiding the Jordanian 
couple Zhang had already carried out an MRT procedure in 2003, in China.[28] On that 
occasion he employed PNT to aid a woman with a non-mtDNA disease infertility problem (she 
had had two failed IVFs after embryo arrest) and a triple pregnancy ensued. No live delivery 
from that pregnancy followed.  
     
When Hamzelou broke the news about the live delivery there had not been any press release 
on behalf of the family or scientists, nor any scientific paper published on this case. In fact, 
the timing of publication of the New Scientist article suggests that Hamzelou got her scoop 
from the program of the 2016 American Society for Reproductive Medicine (ASRM) Scientific 
Congress & Expo, which was available online since the 31st of August 2016.[29] The former is 
relevant because up to the publication of Dr. Zhang et al.’s paper - and an accompanying 
critical editorial - on the 3rd of April 2017 all the information known about this case was limited 
to that which appeared in: a) the ASRM abstract; b) the media interviews that Dr. Zhang and 
the Mexican physician involved in this case, Dr. Alejandro Chavez-Badiola, gave; and c) a video 
recording of Dr. Zhang’s presentation at the ASRM congress.[30,31] 
 
At this point we can confidently assert that this novel case in reproductive medicine had 
significant shortcomings in terms of science transparency and communication. Mainly, that 
after the news broke it took Zhang’s team more than five months to publish the whole 
account of this case, and by that moment harm had already been done to the political stance 
of reproductive medicine in Mexico.[32,33] I will expand on this point next. While it is true 
that publishing in scientific journals takes months, and sometimes years, it is also true that 
the baby was already five months old when the news broke; and that up to that moment 
Zhang and his team had more than enough time to produce a press release - one that clarified 
what was done and where. Doing the former, after the news broke, would have aided in 
cooling down the international political animus in terms of the governance of new 
reproductive techniques.  
  
Mexico and MRTs 
 
In the New Scientist article Dr. Zhang was quoted as saying that he and his team went to the 
neighbouring country because in Mexico “there are no rules”.[2] This quote was very 
controversial, and it ended up being repeated in the press over and over  again. However, a 
quote such as this is not very informative because it does not tell us what there are no rules 
about. If we accept its most charitable interpretation then we can presume that Zhang’s 
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comment was aimed at the regulatory landscape of MRTs in Mexico. In addition to the 
supposed lack of applicable legislation on MRTs, a foreign destination seemed more than 
convenient for carrying out this procedure, given that in the US MRTs are de facto banned.[34] 
In the US it is impossible to legally carry out MRTs, because the Consolidated Appropriation 
Act of 2016, approved by Congress, prohibits the Food and Drug Administration from even 
reviewing applications to carry out research “in which a human embryo is intentionally 
created or modified to include a heritable genetic modification.”[35] In recent work Eli Adashi 
and Glenn Cohen have argued that this moratorium, that was in fact aimed at nuclear 
germline modifications, should be revised and MRTs allowed.[36] It should be remembered 
that the US Institute of Medicine concluded, in their report on MRTs (that was released on 
the 3rd of February 2016), that it was ethically permissible to move ahead with the first-in-
human clinical trials of MRTs, but on the condition that only male embryos were 
transferred.[37] This condition, which is not part of the UK regulations, was attached so as to 
prevent third party mitochondria being passed to further generations.  
 
The fact that this MRT procedure supposedly happened in Mexico took the Mexican scientific 
community by surprise, and the timing of the news, in terms of the regulatory landscape of 
reproductive medicine, could not have been worse. Just six days before the news broke – on 
the 21st of September 2016 – the Health Commission of the Mexican Chamber of Deputies 
approved an amendment to the Mexican General Health Law, the highest federal level 
legislation in matters of health, heavily restricting assisted reproduction and banning all 
embryo research.[38] Fortunately for Mexican scientists, physicians, and fertility patients, the 
bill was stopped before it was voted on the floor. This was very good news, since the 
reproductive rights of such fertility patients, for example, were not affected by ill-thought 
legislation. Stopping this legislation was achieved after substantive activism from academics, 
scientists, and human rights activists. Although at this point the bill is ‘frozen’ it can still be 
submitted for a vote any day. Now, even though the bill preceded the MRT news, it seems 
that any further attempt to pass it into law will include some provision banning MRTs. This 
seems the case given that, when asked about MRTs, the federal deputy (from the 
conservative political party National Action Party) who proposed the new amendments to the 
General Health Law asserted that they will seek to “prohibit pronuclear transfer techniques 
that allow for three parent embryos, since many abuses can happen at the moment of 
carrying out these experiments”.[39]  
 
Now, starting from the assumption that the MRT procedure happened in Mexico, Palacios-
González and Medina-Arellano examined the legal standing of MRTs in such country.[40] They 
reached three conclusions. First, in nine states - out of 32 - PNT is prohibited beacuse state 
laws protect human life from the moment of fertilisation. And in the State of Mexico City 
(formerly the Federal District) PNT is prohibited if the would-be-enucleated embryo is first 
created for a non-reproductive purpose. If the embryo is first created for a reproductive 
purpose and then it is used for an MRT then that would not violate such state law.  
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Second, even though in Mexico there are no federal laws concerning assisted reproduction, 
there are regulations that do apply to MRTs: the Regulations of the General Health Law on 
Health Research. According to Palacios-González and Medina-Arellano’s interpretation of the 
law, and what was publicly known at that time, they concluded that Zhang’s team violated 
Article 56 of aforementioned regulations. They reached this conclusion because Article 56 
establishes that research on assisted fertilization: “will only be admissible when it is applied 
to solve sterility problems that cannot be solved otherwise [emphasis added], respecting the 
couple’s moral, cultural, and social point of view, even if these differ from those of the 
researcher”.[41] And in this case Zhang’s team helped a woman who according to Mexican 
legislation is not sterile, and thus do not have sterility problems, to have a genetically related 
child. Tetsuya Ishii[42] has argued that this woman in fact suffered from sterility problems, 
however Palacios-González and Medina-Arellano[43] have defended that sterility under 
Mexican legislation should be understood following the WHO’s definition of primary 
infertility:  
 
When a woman is unable to ever bear a child, either due to the inability to become 
pregnant or the inability to carry a pregnancy to a live birth she would be classified as 
having primary infertility. Thus women whose pregnancy spontaneously miscarries, or 
whose pregnancy results in a still born child, without ever having had a live birth would 
present with primarily infertility.[44] 
 
It is important to emphasize that with the publication of Zhang’s paper describing this case, 
and the accompanying critical editorial, it became known that the MRT process did not 
happen in Mexico, but rather that it happened in the US.[33,43] In Mexico only the embryo 
transfer procedure took place. This means that they imported a modified embryo across the 
border.[45] It is also important to note that Dr. Alejandro Chavez-Badiola, the Medical 
Director of New Hope Fertility Center Mexico, which is part of Zhang’s fertility clinics, did not 
clarify this point. He did not do so even when in TV interviews he was explicitly asked about 
the role of Mexico in the development of MRT technology and how this live birth was 
accomplished.[30] 
 
The third, and final, conclusion is that MRT research can still legally happen in Mexico, both 
for avoiding mtDNA diseases, and for helping non-mtDNA disease related infertile women or 
couples.  In order for this to happen legally scientists must follow: the laws and regulations 
governing human medical experimentation; article 56 of the Regulations of the General 
Health Law on Health Research; and, when appropriate, state laws that protect life from the 
moment of fertilization.  
 
We now have a clear timeline regarding how this MRT case developed, how it could affect 
future legislation on assisted reproduction in Mexico, and how MRTs can be legally carried 
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out in Mexico. We must now investigate whether Mexican authorities had any role in this 
case. Through freedom of information requests we asked specific Mexican authorities if 
Zhang’s team had approached them to seek advice prior to carrying out the MRT-embryo 
transfer. According to the information we received, through such requests, the following 
institutions were not consulted, or aware, of the MRT procedure: the National Council on 
Bioethics; the Commission for the Protection Against Sanitary Risks of the State of Jalisco, the 
National Centre for Gender Equality and Reproductive Health; the Secretary of Health of the 
State of Jalisco; and the Secretary of Health. The Federal Commission for the Protection 
Against Sanitary Risks, on the other hand, told us that they in fact were consulted on the 
legality of this case, but they did not reveal what was their stance on its legality. It is important 
to point out that the fact the Federal Commission for the Protection Against Sanitary Risks 
was consulted on this matter makes little sense from a legal standpoint. This is because the 
Commission’s remit in regards to reproductive clinics is just to certify the working spaces, and 
not the procedures that take place in them. Furthermore, from a regulatory standpoint the 
Commission would not be able to comment on the legality of such procedure without 
breaching the regulations that govern it, since legal advisory functions on matters of 
reproductive medicine fall outside the Commission’s regulatory remit.[46] 
 
In terms of Mexican legislation, Zhang’s team was not required to seek advice from the 
Secretary of Health on this matter. However the fact that they did not do so shows a disregard 
for the socio-political situation of reproductive medicine in Mexico. Mexico is a country where 
Catholicism is still the dominant religion and where the vast majority of society is conservative 
in terms of reproductive medicine, and thus it should have been obvious that this MRT case 
would cause a great stir. It did so to the point that it dominated the Mexican news cycle 
immediately after the news broke and for the following week. Seeking advice from the 
Secretary of Health, either at a state level or a federal one, and then communicating explicitly 
about this would have mitigated any claim that Mexico is a lawless country, and that Mexico 
and other nations are in need of an urgent reactive prohibitory legislation on MRTs and other 
new reproductive technologies.[47] Eli Adashi and Glenn Cohen have asserted that regulatory 
legislation should strive to be “timely in its enactment, transparent in its prosecution, 
evidence-grounded in its rationale, deliberative in its process, civic-minded in its outreach, 
representative in its inclusiveness, and measured in its scope”.[36] Predictably, a novel use of 
a reproductive technology, like Zhang’s, short-circuits this process and instead helps those 
groups that want to restrict reproductive medicine in general. 
 
Conclusion 
 
There were three main problems with Zhang’s MRT procedure, at least within the context of 
reproductive medicine in Mexico. First, they did not keep the adequate Mexican authorities, 
at the state and federal level, informed about the procedure, and its relevance within the 
international reproductive scientific landscape. Second, there was very poor science 
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communication about this case. There was no press release on behalf of the scientists 
involved in this procedure, at least not one in Spanish. As a result, misinformation spread 
about this MRT case, in which Mexico was presented as a lawless place. Third, there was an 
utter disregard for the medico-political landscape of reproductive medicine in Mexico. In the 
end it is not only that this case could lead to the banning of MRTs in Mexico, but that it could 
help in advancing a federal restrictive legislation that would affect most patients in need of 
reproductive medicine, violating their reproductive rights. Importantly, recall here that not 
all patients can travel abroad to receive reproductive care. In conclusion, Dr. Zhang’s actions 
should be considered as the antithesis of a blueprint for carrying out a new reproductive 
technique.  
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